Ibandronic Acid

CHEMBL997 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
319.2 g/mol
LogP
-4.1
Phase
4

This is the acid form of ibandronate, a bisphosphonate medication that prevents bone loss by inhibiting the bone-resorbing activity of osteoclasts. It is used to treat osteoporosis, reduce fracture risk, and manage hypercalcemia of malignancy and bone metastases. Patients taking oral forms should remain upright after swallowing to minimize esophageal irritation.

Khối lượng phân tử

319,2300 g/mol

LogP

-4,10

TPSA

139,00 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Cơ chế tác dụng

Binds to hydroxyapatite crystals in bone, inhibiting osteoclast-mediated bone resorption by disrupting the mevalonate pathway within osteoclasts. This reduces bone turnover and increases bone mineral density.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Binds to hydroxyapatite crystals in bone, inhibiting osteoclast-mediated bone resorption by disrupting the mevalonate pathway within osteoclasts. This reduces bone turnover and increases bone mineral density.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O

InChI

InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)

Molecular Formula

C9H23NO7P2

HBD / HBA

5 / 8

Liên kết có thể quay

9

Nguyên tử nặng

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

This is the acid form of ibandronate, a bisphosphonate medication that prevents bone loss by inhibiting the bone-resorbing activity of osteoclasts. It is used to treat osteoporosis, reduce fracture risk, and manage hypercalcemia of malignancy and bone metastases. Patients taking oral forms should remain upright after swallowing to minimize esophageal irritation.

Binds to hydroxyapatite crystals in bone, inhibiting osteoclast-mediated bone resorption by disrupting the mevalonate pathway within osteoclasts. This reduces bone turnover and increases bone mineral density.

Yes, Ibandronic Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL997. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 60852. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.